Ligand Pharma Release Promising Results Of Phase I Retinoid Therapy

22 September 1996

- Ligand Pharmaceuticals has released preclinical results of its retinoid therapy, Tagretin (LGD-1069). The study shows it may be useful in the treatment of Type II diabetes as it significantly reduces blood glucose, triglyceride and insulin levels, and in the treatment and prevention of breast cancer, as in animal models it was equally efficacious to tamoxifen in reducing tumor frequency, without the weight loss side effects.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight